Standout Papers

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Pr... 2004 2026 2011 2018 2.8k
  1. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer (2004)
    Daniel P. Petrylak, Catherine M. Tangen et al. New England Journal of Medicine
  2. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer (2015)
    Christopher J. Sweeney, Yu‐Hui Chen et al. New England Journal of Medicine
  3. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group (2008)
    Howard I. Scher, Susan Halabi et al. Journal of Clinical Oncology
  4. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial (2018)
    Christos E. Kyriakopoulos, Yu‐Hui Chen et al. Journal of Clinical Oncology
  5. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer (2018)
    Maha Hussain, Karim Fizazi et al. New England Journal of Medicine
  6. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer (2020)
    Cora N. Sternberg, Karim Fizazi et al. New England Journal of Medicine
  7. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). (2022)
    Xīn Gào, Howard A. Burris et al. Journal of Clinical Oncology
  8. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial (2023)
    Maha Hussain, Bertrand Tombal et al. Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 3 from Science/Nature 120 standout
Sub-graph 1 of 13

Citing Papers

Prostate Cancer
2025 Standout
CDK4 and CDK6 kinases: From basic science to cancer therapy
2022 StandoutScience
91 intermediate papers

Works of Maha Hussain being referenced

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
and 45 more

Author Peers

Author Last Decade Papers Cites
Maha Hussain 12911 6087 3895 4348 355 18.0k
Mario A. Eisenberger 20808 8308 6040 6219 375 26.6k
Kurt Miller 8902 2897 2616 3462 350 14.4k
Kim N. 19731 8367 6355 7722 359 25.2k
Ronald de Wit 13147 10045 4059 4351 371 25.7k
Nicholas D. James 6964 4581 2316 2412 335 13.2k
Joel Picus 8932 9106 2101 4488 223 17.7k
Neal D. Shore 16380 9214 5377 4654 752 24.3k
Daniel P. Petrylak 10428 10847 3127 3272 521 22.4k
Peter F.A. Mulders 12329 3502 2566 3872 202 16.2k
David M. Nanus 8050 4890 2485 3488 326 14.4k

All Works

Loading papers...

Rankless by CCL
2026